Company Overview

PRIME exits and American Healthcare Capital is pleased to exclusively introduce an innovative MedTech inventor and developer that has created a technology breakthrough, patent-protected Airway Device. This device is designed to reduce or eliminate hypoxia during difficult intubations, marking a significant advancement in emergency medical technology. The device has demonstrated remarkable results in preclinical trials and promises to be a game-changer in emergency and critical care settings. Research has shown that in large animals whose breathing had stopped, the Airway Device maintained oxygen levels above 97% for over 16 minutes.

Financial Forecast

The product line will be ending its pre-revenue stage by the end of 2024. Contract manufacturing has been engaged and sales distribution is in progress for its FDA-cleared innovative device. The device is expected to have a 60% to 70% gross profit margin, which will increase with scale. The preferred channel of distribution for this product will be to combine with the endotracheal tube market segment. This will be utilized for emergency treatment in hospitals, ambulatory surgery centers, specialty clinics, and research centers. The Company is forecasting $50 million in revenues in 2027 with an EBITDA of $17.6 million (35%).

Asking Price

The Price is to Be Determined, with or without an Earnout Going Forward.